Stephens Investment Management Group LLC Grows Stock Position in Repligen Corporation $RGEN

Stephens Investment Management Group LLC increased its holdings in Repligen Corporation (NASDAQ:RGEN) by 14.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 598,356 shares of the biotechnology company’s stock after buying an additional 75,509 shares during the quarter. Stephens Investment Management Group LLC owned 1.06% of Repligen worth $79,982,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. DekaBank Deutsche Girozentrale boosted its stake in shares of Repligen by 1.0% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 7,830 shares of the biotechnology company’s stock worth $961,000 after acquiring an additional 80 shares during the last quarter. Drive Wealth Management LLC increased its stake in shares of Repligen by 2.5% in the 2nd quarter. Drive Wealth Management LLC now owns 3,796 shares of the biotechnology company’s stock worth $472,000 after purchasing an additional 93 shares in the last quarter. Hilltop National Bank raised its holdings in Repligen by 8.0% in the 3rd quarter. Hilltop National Bank now owns 1,276 shares of the biotechnology company’s stock worth $171,000 after purchasing an additional 95 shares during the period. ProShare Advisors LLC lifted its position in Repligen by 4.3% during the second quarter. ProShare Advisors LLC now owns 2,316 shares of the biotechnology company’s stock valued at $288,000 after purchasing an additional 96 shares in the last quarter. Finally, Louisiana State Employees Retirement System grew its holdings in Repligen by 0.7% during the second quarter. Louisiana State Employees Retirement System now owns 14,700 shares of the biotechnology company’s stock valued at $1,828,000 after purchasing an additional 100 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Karen A. Dawes sold 275 shares of Repligen stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $161.00, for a total value of $44,275.00. Following the sale, the director directly owned 91,821 shares of the company’s stock, valued at approximately $14,783,181. The trade was a 0.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO James Bylund sold 2,191 shares of the business’s stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $151.21, for a total value of $331,301.11. Following the completion of the sale, the chief operating officer owned 21,520 shares in the company, valued at $3,254,039.20. This represents a 9.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 49,657 shares of company stock worth $7,721,077 over the last 90 days. Corporate insiders own 1.20% of the company’s stock.

Repligen Trading Up 0.2%

Repligen stock opened at $162.02 on Friday. Repligen Corporation has a 1 year low of $102.96 and a 1 year high of $182.52. The firm’s 50 day moving average price is $162.68 and its 200-day moving average price is $141.51. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.36 and a quick ratio of 7.14. The stock has a market cap of $9.12 billion, a P/E ratio of 8,105.05, a PEG ratio of 2.93 and a beta of 1.12.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, October 28th. The biotechnology company reported $0.46 earnings per share for the quarter, topping analysts’ consensus estimates of $0.42 by $0.04. The firm had revenue of $188.81 million during the quarter, compared to analyst estimates of $181.23 million. Repligen had a net margin of 0.25% and a return on equity of 4.66%. Repligen’s revenue for the quarter was up 21.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.43 earnings per share. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. On average, equities analysts predict that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Analyst Ratings Changes

RGEN has been the subject of a number of analyst reports. Jefferies Financial Group set a $160.00 price target on Repligen and gave the stock a “hold” rating in a research report on Tuesday, October 28th. Barclays increased their target price on shares of Repligen from $175.00 to $200.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. Wall Street Zen cut shares of Repligen from a “buy” rating to a “hold” rating in a research note on Tuesday, November 4th. Wells Fargo & Company upped their price target on shares of Repligen from $175.00 to $190.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Finally, Canaccord Genuity Group increased their price objective on shares of Repligen from $150.00 to $165.00 and gave the stock a “hold” rating in a research note on Wednesday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $179.62.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.